The following is a summary of “Safety and efficacy of palliative transurethral resection of the prostate for lower urinary ...

Metastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

The viral immunotherapy delivers a replication-defective herpes simplex virus thymidine kinase gene and was administered in ...